ClinicalTrials.gg
Active, not recruitingNCT05712473Updated Sep 15, 2026

An Observational Registry Assessing the Impact of PYLARIFY® (Piflufolastat F18) PET in Patients With Prostate Cancer

An observational study in Prostate Cancer, sponsored by Lantheus Medical Imaging. Active, not recruiting at 12 sites in United States. Open to male participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Lantheus Medical Imaging (part of Lantheus Holdings, Inc.) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
21 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Prostatic Neoplasms by Lantheus Holdings, Inc. — 1 open to participants now, 2 under way, 1 of them phase 3. Prostatic Neoplasms · Lantheus Holdings, Inc..

Started
2023
the only one that year
Observational
2 of 22
none open now
Registered
20th of 22
by date

Among the 22 studies in Prostatic Neoplasms by Lantheus Holdings, Inc., this one is the only one that started in 2023, is one of 2 observational ones, and was the 20th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

1 of the 22 studies in Prostatic Neoplasms by Lantheus Holdings, Inc. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 21 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Prostatic Neoplasms by Lantheus Holdings, Inc., or all of them as a file.
02

Study summary

The goal of this observational research is to assess the real-world clinical utility of PYLARIFY PET through evaluation of long-term outcomes for prostate cancer patients who are eligible for a PSMA/PET scan.

Participants will be enrolled at their physician's office at the time of referral for PYLARIFY PET and will be followed for up to 5 years. Data concerning their prostate cancer diagnostics and treatment will be collected at 6-month intervals.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Biologically male patients with confirmed prostate cancer referred to undergo a PSMA PET with PYLARIFY.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet all the following inclusion criteria:

  1. Biological male at birth ≥ 21 years of age
  2. Histopathological confirmed prostate adenocarcinoma
  3. Patients meeting the enrollment criteria for either Cohort 1 or Cohort 2:

    1. Cohort 1:

      Patients who are newly diagnosed with prostate cancer (and have suspected per the physician's discretion per standard of care assessment) and have not yet initiated any prostate cancer treatment and are referred to undergo PYLARIFY PET for identification of suspected metastases.

      OR

    2. Cohort 2:

    Patients who have previously received treatment for prostate cancer and are referred to undergo PYLARIFY PET or have received PYLARIFY PET for suspected recurrence of prostate cancer (based on an elevated PSA) within 60 days of consent to enroll in the registry

  4. ≥ 6 months as determined by the investigator
  5. Able and willing to provide and comply with the protocol requirements.

Exclusion criteria

Exclusion Criteria:

Patients meeting any of the following exclusion criteria are not eligible for enrollment in this study:

  1. Patients who are referred for PSMA PET and undergo a PSMA PET with a radioactive agent other than PYLARIFY
  2. Patients who have histological evidence of neuroendocrine prostate cancer (NEPC) (small cell/ductal variant)
  3. Patients with any medical condition or other circumstances that, in the opinion of the investigator, compromise the safety of compliance of the patient to produce reliable data or completing the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Cohort 1

    Patients who are newly diagnosed with prostate cancer (and have suspected metastases) and have not yet initiated any prostate cancer treatment and are referred to undergo PYLARIFY PET

    Diagnostic Test: PYLARIFY

  • Cohort 2:

    Patients who have previously received treatment for prostate cancer and are referred to undergo PYLARIFY PET or have received PYLARIFY PET for suspected recurrence of prostate cancer (based on an elevated PSA) within 60 days of consent to enroll in the registry

    Diagnostic Test: PYLARIFY

Interventions

  • Diagnostic testPYLARIFY

    PYLARIFY PET

06

What researchers measure

Primary outcomes

  1. Primary Objective

    The objective of this registry is to assess the real-world clinical utility of PYLARIFY PET through evaluation of long-term outcomes for prostate cancer patients who are eligible for a PSMA/PET scan and for whom PYLARIFY imaging is incorporated into treatment recommendations and management plans.

    Time frame: 5 years

Secondary outcomes

  1. Secondary Objective 1

    To understand the demographic and clinical characteristics of patients referred for PYLARIFY PET.

    Time frame: 5 years

  2. Secondary Objective 2

    To understand the impact of PYLARIFY PET results on healthcare resource utilization.

    Time frame: 5 years

  3. Secondary Objective 3

    To understand the role of PYLARIFY PET in treatment change management for newly diagnosed prostate cancer patients.

    Time frame: 5 years

  4. Secondary Objective 4

    To understand the utilization of PYLARIFY PET at very low PSA levels in patients with oligometastatic prostate cancer.

    Time frame: 5 years

  5. Secondary Objective 5

    To understand racial and ethnic disparities in prostate cancer care.

    Time frame: 5 years

07

Study locations

12 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Feb 2031, 93 months after the start.

Of 109 industry-sponsored observational studies under Prostatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 65. This study's planned 93 months is above that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2023
First posted
Feb 3, 2023
StartActual
May 22, 2023
Primary completionEst.
Feb 2031
CompletionEst.
May 2031
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05712473
Collaborators
Specialty Networks Research.
Responsible party
Sponsor
First posted
Feb 3, 2023
Start date
May 22, 2023
Primary completion
Feb 2031 (estimated)
Completion
May 2031 (estimated)
Last update
Sep 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion